Eli Lilly is a global healthcare company that focuses on the discovery, development, and commercialization of pharmaceuticals. Its core products include treatments for diabetes, oncology, immunology, and neurodegenerative diseases. Major business segments consist of diabetes care, oncology, and neuroscience, with significant revenue generated from insulin products and cancer therapies. The company is recognized for its innovative drug pipeline and strong market presence in the healthcare sector.
Eli Lilly's stock is positioned as a balanced investment, appealing to investors seeking moderate growth and some income through dividends. The company demonstrates stable revenue growth and a consistent dividend yield, making it suitable for those looking for a mix of capital appreciation and income. Its established market presence and ongoing product development contribute to a favorable risk-return profile.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-05-18 04:09 | Hold | Buy | Strong fundamentals and positive short-term momentum. |
| 2026-05-10 02:33 | Buy | Hold | Weak momentum and high risk; mixed analyst signals. |
| 2026-05-08 14:57 | — | Buy | Solid fundamentals but mixed momentum signals. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-06-09 15:51 | Jefferies | Target Raised | 1330 → 1350 | 1143.35 |
| 2026-05-26 09:26 | HSBC | Target Raised | — → 1251 | 1065 |
| 2026-05-26 07:05 | Leerink Partners | Update | — → 1119 | 1065 |
